Sanofi Completes Acquisition of Dynavax, Enhancing Presence in Adult Immunization

Sanofi has completed the acquisition of Dynavax, adding Dynavax's adult hepatitis B vaccine HEPLISAV-B and shingles vaccine candidate Z-1018 to its portfolio. The acquisition strengthens Sanofi's presence in adult immunization and provides a two-dose regimen over one month for HEPLISAV-B. Dynavax's vaccine pipeline projects are also included in the deal. The acquisition was completed through a merger and tender offer, with Dynavax becoming an indirect, wholly owned subsidiary of Sanofi.